The Leclaza-Rybrevant combination therapy has emerged as the new standard of care for lung cancer treatment and is now being actively implemented in South Korea's clinical settings.

As results indicate improvements in progression-free survival (PFS) as well as overall survival (OS) compared to Tagrisso (osimertinib, AstraZeneca), Janssen has initiated patient programs at major hospitals.

Then, can this globally emerging standard option be rapidly integrated into clinical settings? Analysis suggests the key factors for successful adoption are effective side effect management and the resolution of cost barriers.

According to industry sources on March 31, the MARIPOSA Phase 3